Literature DB >> 32734645

Cardiovascular disease and COVID-19: Australian and New Zealand consensus statement.

Sarah Zaman1,2, Andrew I MacIsaac3, Garry Lr Jennings4,5, Markus P Schlaich5,6, Sally C Inglis7, Ruth Arnold8, Saurabh Kumar9,10, Liza Thomas4,9, Sudhir Wahi11, Sidney Lo12, Carolyn Naismith13, Stephen J Duffy14,15, Stephen J Nicholls1,2, Andrew Newcomb16, Aubrey A Almeida17,18, Selwyn Wong19, Mayanna Lund19, Derek P Chew20, Leonard Kritharides21,22, Clara K Chow9,10, Ravinay Bhindi23.   

Abstract

INTRODUCTION: The coronavirus 2019 disease (COVID-19) pandemic is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Pre-existing cardiovascular disease (CVD) increases the morbidity and mortality of COVID-19, and COVID-19 itself causes serious cardiac sequelae. Strategies to minimise the risk of viral transmission to health care workers and uninfected cardiac patients while prioritising high quality cardiac care are urgently needed. We conducted a rapid literature appraisal and review of key documents identified by the Cardiac Society of Australia and New Zealand Board and Council members, the Australian and New Zealand Society of Cardiac and Thoracic Surgeons, and key cardiology, surgical and public health opinion leaders. MAIN RECOMMENDATIONS: Common acute cardiac manifestations of COVID-19 include left ventricular dysfunction, heart failure, arrhythmias and acute coronary syndromes. The presence of underlying CVD confers a five- to tenfold higher case fatality rate with COVID-19 disease. Special precautions are needed to avoid viral transmission to this population at risk. Adaptive health care delivery models and resource allocation are required throughout the health care system to address this need. CHANGES IN MANAGEMENT AS A RESULT OF THIS STATEMENT: Cardiovascular health services and cardiovascular health care providers need to recognise the increased risk of COVID-19 among CVD patients, upskill in the management of COVID-19 cardiac manifestations, and reorganise and innovate in service delivery models to meet demands. This consensus statement, endorsed by the Cardiac Society of Australia and New Zealand, the Australian and New Zealand Society of Cardiac and Thoracic Surgeons, the National Heart Foundation of Australia and the High Blood Pressure Research Council of Australia summarises important issues and proposes practical approaches to cardiovascular health care delivery to patients with and without SARS-CoV-2 infection.
© 2020 AMPCo Pty Ltd.

Entities:  

Keywords:  COVID-19; Delivery of healthcare; Heart failure; Infection control; Infectious diseases; Myocardial infarction; Respiratory tract infections

Year:  2020        PMID: 32734645     DOI: 10.5694/mja2.50714

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  19 in total

1.  COVID-19 and the quality use of medicines: evidence, risks and fads.

Authors:  Darren M Roberts; Alexandra Bennett
Journal:  Aust Prescr       Date:  2020-05-08

Review 2.  Management of Osteoarthritis During the COVID-19 Pandemic.

Authors:  Enrico Ragni; Laura Mangiavini; Marco Viganò; Anna Teresa Brini; Giuseppe Michele Peretti; Giuseppe Banfi; Laura de Girolamo
Journal:  Clin Pharmacol Ther       Date:  2020-06-22       Impact factor: 6.903

3.  Criticality of physical/social distancing, handwashing, respiratory hygiene and face-masking during the COVID-19 pandemic and beyond.

Authors:  Farid Rahimi; Amin Talebi Bezmin Abadi
Journal:  Int J Clin Pract       Date:  2020-09-13       Impact factor: 3.149

4.  COVID-19 and chronic obstructive pulmonary disease: therapeutic potential of blocking SARS-CoV2 adhesion factors.

Authors:  Shakti D Shukla; E Haydn Walters
Journal:  Intern Med J       Date:  2020-07-14       Impact factor: 2.611

5.  Cardiovascular Disease in the Post-COVID-19 Era - the Impending Tsunami?

Authors:  Usaid K Allahwala; A Robert Denniss; Sarah Zaman; Ravinay Bhindi
Journal:  Heart Lung Circ       Date:  2020-04-16       Impact factor: 2.975

6.  Coronavirus disease 2019 (COVID-19): angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and cardiovascular disease.

Authors:  Garry Lr Jennings
Journal:  Med J Aust       Date:  2020-05-21       Impact factor: 12.776

Review 7.  COVID-19 infection and cardiac arrhythmias.

Authors:  Antonis S Manolis; Antonis A Manolis; Theodora A Manolis; Evdoxia J Apostolopoulos; Despoina Papatheou; Helen Melita
Journal:  Trends Cardiovasc Med       Date:  2020-08-16       Impact factor: 6.677

8.  COVID-19 and Heart, Lung and Circulation: Riding the 2020 Waves of Change in Australia & New Zealand.

Authors:  Ann T Gregory; Salvatore Pepe; A Robert Denniss
Journal:  Heart Lung Circ       Date:  2020-12       Impact factor: 2.975

Review 9.  Personal protective equipment and evidence-based advice for surgical departments during COVID-19.

Authors:  Lorwai Tan; Joshua G Kovoor; Penny Williamson; David R Tivey; Wendy J Babidge; Trevor G Collinson; Peter J Hewett; Thomas J Hugh; Robert T A Padbury; Sally J Langley; Guy J Maddern
Journal:  ANZ J Surg       Date:  2020-08-18       Impact factor: 2.025

10.  COVID-19 safety: aerosol-generating procedures and cardiothoracic surgery and anaesthesia - Australian and New Zealand consensus statement.

Authors:  Joanne F Irons; Warren Pavey; Jayme S Bennetts; Emily Granger; Elli Tutungi; Aubrey Almeida
Journal:  Med J Aust       Date:  2020-10-11       Impact factor: 12.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.